• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

'Dr. Doom' Nouriel Roubini says we're headed for universal basic income or 'some form of socialism' as AI revolutionizes work—He calls that optimistic

2

Power companies are using eminent domain to seize land for data centers as 70% of Americans say not in my backyard

3

‘I want to die broke’: Billionaire philanthropist Denny Sanford dies after giving away $4 billion

1

'Dr. Doom' Nouriel Roubini says we're headed for universal basic income or 'some form of socialism' as AI revolutionizes work—He calls that optimistic

2

Power companies are using eminent domain to seize land for data centers as 70% of Americans say not in my backyard

3

‘I want to die broke’: Billionaire philanthropist Denny Sanford dies after giving away $4 billion
C-SuitePharmaceutical Industry

The CEO who loves AI autodidacts — and desperately needs his experts

Nick Lichtenberg
By
Nick Lichtenberg
Nick Lichtenberg
Business Editor
Down Arrow Button Icon
Nick Lichtenberg
By
Nick Lichtenberg
Nick Lichtenberg
Business Editor
Down Arrow Button Icon
June 3, 2026, 9:00 AM ET
bb
Amgen CEO Robert "Bob" Bradway.courtesy of Amgen
Add Fortune on Google for similar content.

Bob Bradway has a word for the kind of leader who will thrive in the AI era: “autodidact.” Curious. Self-taught. Comfortable with uncertainty. The kind of person who picks up a new tool on a Saturday and figures it out by Sunday — which, as it happens, is exactly what Bradway himself does.

Recommended Video

The Amgen CEO spends his weekends vibe-coding, has required his entire senior executive team to take AI courses, and talks about artificial intelligence with a rare fluency. In a podcast interview with AI pioneer Andrew Ng, he was told: “A lot of times you sound more like an AI person than a biotech CEO.”

The irony is that Bradway runs a company built on the opposite of the autodidact. Amgen’s competitive moat is its experts — scientists who have spent decades learning that molecules are delicate constructions indeed. “The hallways are full of people who have the experience of understanding if you make a substitution of one amino acid for another, there’s a consequence,” Bradway said. “We want to be very careful not to lose that.”

Reconciling those two things — the adaptable generalist and the irreplaceable specialist — is the central challenge of Bradway’s AI moment. And few CEOs are better positioned to navigate it. That’s because Bradway didn’t just start thinking about AI recently. He started in 2012.

That year, Amgen acquired DeCODE Genetics, a small Icelandic company holding longitudinal genomic data on virtually the entire population of Iceland — not a drug or a patent, but a bet that data and AI would eventually transform how medicines get discovered. His peers were skeptical. Even Andrew Ng, who would later become a close collaborator, told Bradway at the time that the genetic data wasn’t “tractable” yet and steered him toward nearer-term AI applications like computer vision. Bradway made both bets and today, an Nvidia SuperPod hums in Reykjavik, Amgen has developed its own protein folding models, and the company is actively pursuing zero-shot antibody design — using AI to engineer drug molecules without prior experimental examples.

The results are tangible, Bradway said. Amgen is now selecting drug candidates for clinical development roughly 50% faster than before. Rather than relying solely on DeepMind’s celebrated AlphaFold, Bradway pushed his team to look past the hype and identify precisely what the model could and couldn’t do for their specific needs — then build on top of it. “We’re not relying on any single approach,” he said.

Amgen told Fortune that it has several “tangible examples” of how AI is additive and supportive to its teams’ work, with a focus on freeing up time for them to focus on what really moves the needle in terms of getting medicines to patients. It has reduced production line clearance time at one manufacturing site from approximately 30 minutes to about two minutes per batch run, and in certain trials, participants were enrolled up to three times more efficiently, according to the company. AI tools and training available companywide include Microsoft Copilot and OpenAI’s ChatGPT Enterprise, alongside investments in training education and responsible-use frameworks. 

His next frontier is agentic AI, and the timeline is explicit: “2026 is the year we all need to figure out what agentic AI is.” The opportunity, as he described it, is profound: scientists today burn hours filling out forms, requisitioning materials, summarizing data — work that agentic systems could absorb entirely, freeing researchers to do what only they can do. “That’s magic,” he said. It’s also where the autodidact-versus-expert tension gets resolved, in Bradway’s telling: AI is liberating, rather than displacing. “Hopefully they have more time to use the essence of their skill,” he said, “and less time devoted to menial things.”

Whether that reassurance lands with employees is another matter. Bradway acknowledged that America broadly doesn’t trust AI and that uncertainty breeds anxiety. “There is a lot of misinformation and there’s a lot of uncertainty and humans hate the unknown, right? Humans don’t like to be kept in the dark and so the more we can share transparently what we’re doing, I think the better.” Still, he admitted, “I don’t have the answer to that, although as you can see, I’m an optimist.”

He’s also, at this point, a proven one. While other CEOs are still debating AI’s return on investment, Bradway is openly baffled by the hand-wringing. “I read a lot and hear a lot about people expressing frustration that they’re not earning a return from the investments that they’re making. I’m a little bit puzzled by that,” he said. Then again, he noted that in biotech, patience isn’t optional and a single molecule can consume a decade-and-a-half, so maybe his “bewilderment” is down to the different calculus. The companies that can’t tolerate uncertainty, he implied, may be precisely the ones that fall behind.

Historically, the process with molecules has relied heavily on iterative laboratory work, manual data review and sequential testing, and AI can help researchers analyze significantly larger datasets, model molecular behavior, predict protein structures, and evaluate candidate molecules earlier in the process. The goal, Amgen said, is to deprioritize less promising candidates earlier. 

“Being late to this party is going to be expensive,” he said. “Being early to the party has the potential for real benefit.”

For this story, Fortune journalists used generative AI as a research tool. An editor verified the accuracy of the information before publishing.

Subscribe to Fortune Gulf Brief. Every Tuesday, this new newsletter delivers clear-eyed, authoritative intelligence on the deals, decisions, policies, and power shifts shaping one of the world’s most consequential regions, written for the people who need to act on it. Sign up here.
About the Author
Nick Lichtenberg
By Nick LichtenbergBusiness Editor
LinkedIn icon

Nick Lichtenberg is business editor and was formerly Fortune's executive editor of global news.

See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in C-Suite

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in C-Suite

Volvo car CEO pushes back on Navarro’s ‘Pirate’ China comments
EuropeVolvo
Volvo car CEO pushes back on Navarro’s ‘Pirate’ China comments
By Rafaela Lindeberg and BloombergJuly 20, 2026
5 hours ago
Artificial Intelligence technology and futuristic technology transformation
C-SuiteCFO Daily
How CFOs can tell if AI is actually creating value
By Sheryl EstradaJuly 20, 2026
7 hours ago
andy
PoliticsUnited Kingdom
Andy Burnham accuses UK of taking wrong turns since the 1980s in first speech as Prime Minister outside 10 Downing Street
By Jill Lawless and The Associated PressJuly 20, 2026
7 hours ago
C-suite promotions now come with three or more jobs
C-SuiteNext to Lead
C-suite promotions now come with three or more jobs
By Ruth UmohJuly 20, 2026
8 hours ago
Nestlé KitKat Original chocolate bars
RetailMarketing
How Nestlé turned a chocolate heist into a masterclass in brand building 
By Sam BirchallJuly 20, 2026
11 hours ago
biden
CommentaryLeadership
Ginsburg and Biden’s blind spot: when leaders don’t know when to leave
By Michael SonnenfeldtJuly 19, 2026
1 day ago

Most Popular

'Dr. Doom' Nouriel Roubini says we're headed for universal basic income or 'some form of socialism' as AI revolutionizes work—He calls that optimistic
AI
'Dr. Doom' Nouriel Roubini says we're headed for universal basic income or 'some form of socialism' as AI revolutionizes work—He calls that optimistic
By Jason MaJuly 18, 2026
2 days ago
Power companies are using eminent domain to seize land for data centers as 70% of Americans say not in my backyard
AI
Power companies are using eminent domain to seize land for data centers as 70% of Americans say not in my backyard
By Aaron Walayat and The ConversationJuly 19, 2026
1 day ago
‘I want to die broke’: Billionaire philanthropist Denny Sanford dies after giving away $4 billion
Success
‘I want to die broke’: Billionaire philanthropist Denny Sanford dies after giving away $4 billion
By Sydney LakeJuly 20, 2026
6 hours ago
Red Lobster’s 37-year-old CEO waited tables before joining the C-suite—he says it was a crash course in managing ‘difficult people and situations’
Success
Red Lobster’s 37-year-old CEO waited tables before joining the C-suite—he says it was a crash course in managing ‘difficult people and situations’
By Preston ForeJuly 19, 2026
2 days ago
Warren Buffett says his $147 billion investing career was an accident: ‘I may be one of the 10 luckiest in the world’
Future of Work
Warren Buffett says his $147 billion investing career was an accident: ‘I may be one of the 10 luckiest in the world’
By Sarah GlodekJuly 20, 2026
13 hours ago
It’s not just Taco Bell lettuce and possible glass in Pillsbury rolls: Food and drink recall events reached a 6-year year-over-year high
Retail
It’s not just Taco Bell lettuce and possible glass in Pillsbury rolls: Food and drink recall events reached a 6-year year-over-year high
By Sasha RogelbergJuly 20, 2026
10 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.